Multiple proliferative pathways and macromolecular targets

The term Multiple proliferative pathways and macromolecular targets does not refer to a single biological molecule, receptor, or enzyme, but rather describes a broad pharmacological profile or therapeutic strategy. This concept is central to polypharmacology, where a single drug or a combination of agents is designed to interact with various signaling nodes—such as the PI3K/Akt/mTOR and MAPK/ERK pathways—and structural components like DNA or microtubules simultaneously (Source: Nature Reviews Drug Discovery, 2019). In the context of oncology, targeting multiple pathways is often necessary to prevent the emergence of resistance caused by cellular crosstalk and bypass mechanisms (Source: Cell, 2011). Because this entry encompasses a wide array of unrelated proteins and physiological processes, it is classified as an incorrect target designation for structured biochemical data. It represents a functional category of drug action rather than a specific, isolatable therapeutic target. Consequently, it lacks a unique UniProt ID or a specific molecular structure, making it a descriptive term for multi-target activity in complex diseases like cancer.

Other names

Multi-target therapyPolypharmacology targetsNetwork pharmacology targets

Simultaneous inhibition or modulation of multiple distinct signaling cascades and cellular components to overcome pathway redundancy and drug resistance.